A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

Neurology

Volumn 39, Issue 8, 1989, Pages 1018-1026

  Tourtellotte, W W ^a,b   Syndulko, K ^a,b   Pettler Jennings, P ^b   Holevoet Howson, M I ^a   Lerner, C D ^a   Frane, M V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE;

ADULT; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AZATHIOPRINE; CLINICAL TRIALS; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0024462396     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.39.8.1018     Document Type: Article

References (50)

1. Lieak RP. Immunopathogenic mechanisms, abnormal immunoregulation, and immunomodulating therapy in multiple sclerosis (clinical aspects). Autoimmunity 1987;1:14–21.
2. Waksman BH. Mechanisms in multiple sclerosis. Nature (Lond) 1985;318:104–105.
3. Ellison GW. Treatment aimed at modifying the course of multiple sclerosis. In: McDonald WI. Silberberg DH, eds. Multiple sclerosis. London: Buttersworths, 1987:2153–165.
4. Hughes RA. Immunological treatment of multiple sclerosis. II. J Neurol 1986;233:66–68.
5. Ellison GW, Myers LW. Immunosuppressive druge in multiple sclerosis: pro and con. Neurology 1980;30:28–32.
6. Patzold U, Hecker H, Pocklington P. Azathioprine in treatment of multiple sclerosis: final results of a 41/2 year controlled study of its effectiveness covering 115 patients. J Neurol Sci 1982;54:377–394.
7. Rosen JA. Prolonged azathioprine treatment of non-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1979;42:338–344.
8. Dau PC, Petajan JH, Johnson KP, et al. Plasmapheresis and immunosuppressive drug therapy in multiple sclerosis. Neurology 1979;29:573.
9. Tucker WG., Kapphahn KH. A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis. Henry Ford Hosp Med J 1963;17:89–92.
10. Zeeberg I, Heltberg A, Kristensen JH, Raun NE, Fog T. Azathioprine (Imuran) v. placebo in treatment of progressive multiple sclerosis. In: Hommes OR, Mertin J, Tourtellotte WW, eds. Immunotherapies in multiple sclerosis. Sutton, UK: Stuart Phillips, 1986:295–300.
11. Silberberg D, Lisak R, Zweiman B. Multiple sclerosis unaffected by azathioprine in pilot study. Arch Neurol 1973;28:210–212.
12. Swinburn WR, Liversedge LA. Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry 1973;36:124–126.
13. Millar JHD, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD. Long-term treatment of multiple sclerosis with corticotrophin. Lancet 1967;2:429–431.
14. Tourtellotte WW, Haerer AF. Use of oral corticosteroids in the treatment of multiple sclerosis. Arch Neurol 1965; 12:536–545.
15. Fog T. The long-term treatment of multiple sclerosis with corticosteroids. Acta Neurol Scand (Suppl) 1965;13:473–484.
16. Levy J. Comparative effects of azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. In: Rosenthal ME, Mansman HC Jr, eds. Immunopharmacology. Baltimore: University Park Press, 1975:205–212.
17. Barnett EV, Dornfeld L, Lee DBN, Liebling MR. Longterm survival of lupus nephritis patients treated with azathioprine and prednisone. J Rheumatol 1978;5:275–283.
18. Ginzler E, Diamond H, Guttadauria M, Kaplan D. Prednisone: and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse, lupus nephritis. Arthritis Rheum 1976;19:693–699.
19. Decker JL, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial—results at 28 months. Ann Intern Med 1975;83:606–615.
20. Ellison GW, Myers LW, Mickey MR, et al. Therapeutic trials in multiple sclerosis: azathioprine. Ann NY Acad Sci 1984;436:361–365.
21. Myers LW, Mickey MR, Ellison GW. Preliminary trial of azathioprine (Imuran) and steroids in multiple sclerosis. In: Hommes OR, Mertin J, Tourtellotte WW, eds. Immunotherapies in multiple sclerosis. Sutton, UK: Stuart Phillips Publications, 1986:287–293.
22. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231.
23. Schumacher GA, Beebe G, Kibler RE, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552–568.
24. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo—final report. Neurology 1970;20:1–59.
25. Mickey MR, Ellison GW, Myers LW. An illness severity score for multiple sclerosis. Neurology 1984;34:1343–1347.
26. Hommes OR, Prick JJG, Lamers KJB. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 1975;78:59–72.
27. Kurtzke JF. The disability statue scale for multiple sclerosis: apologia pro DSS sua. Neurology 1989;39:291–302.
28. Tourtellotte WW, Syndulko K, Baumhefner RW, Shapshak P, Osborne M. A comprehensive protocol for clinical trials in multiple sclerosis which favored azathioprine and corticosteroid as a type of treatment for the chronic progressive phase. Neurology 1988;38(Suppl 2):83–86.
29. Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide ‘pulses’ in chronic progressive multiple sclerosis: a preliminary clinical trial. Arch Neurol 1987;44:828–832.
30. Potvin AR, Tourtellotte WW, Potvin JH, Kondraske GV, Syndulko K. Quantitative examination of neurologic functions, vol 1. Scientific basis and design of instrumented testa. Boca Raton, FL: CRC Press, 1985:221–239.
31. Potvin AR, Syndulko K, Tourtellotte WW, Lemmon JA, Potvin JH. Human neurological function and the normal aging process. J Am Geriatr Soc 1980;28:1–9.
32. Nuwer MR, Packwood JW, Myers LW, Ellison GW. Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 1987;37:1754–1761.
33. Dixon WJ, ed. BMPD statistical software, 3rd ed. Berkeley, CA: University of California Press, 1984.
34. Kurtzke JF. Neuroepidemiology, part II: assessment of therapeutic trials. Ann Neurol 1986;19:311–319.
35. Fisher RA. The design of experiments, 8th ed. Edinburgh Oliver & Boyd, 1966:44–49.
36. Friedman LM, Furberg CD, De Mets DL. Fundamentals of clinical trials, 2nd ed. Littleton, MA: PSG Publishing, 1985:75.
37. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179–183.
38. Milanese C, et al. Double-blind controlled randomized study on azathioprine efficacy in multiple sclerosis: preliminary results. Ital J Neurol Sci 1988;9:53–57.
39. Minderhoud JM, Prange AJ, Luyckx GJ. A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis. Clin Neurol Neurosurg 1988;90:25–28.
40. Lhermitte F, Marteau R, de Saxce H. Traitament des formes évolutives et graves de sclérose en plaques par I’association sérum antilymphocytaire, azathioprine, prednisone: résultats cliniques et biologiques—comparison avec un groupe témoin traité par azathioprine et prednisone seuls. Surveillance pendant 4 ans. Rev Neurol (Paris) 1987;143:98–107.
41. Sabouraud O, Oger J, Darcel F, Madigand M, Merienne M. Immunosuppression au long cours dane la sclerose en plaques: evaluation des traitements commences avant 1972. Rev Neurol (Paris) 1984;140:125–130.
42. Bijlsma JW, Schenk Y, Rameslaar AG, Huber-Bruning O. Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis. Clin Rheumatol 1986;5:499–504.
43. Hansen TM, Dickmeiss E, Jans H, Ingemann-Hansen T, Ingeman-Nielsen M, Lorenzen I. Combination of methylpredaisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis 1987;46:290–295.
44. Weiner HL, Hafler DA. Immunotherapy of multiple sclerosis. Ann Neurol 1988;23:211–222.
45. Paty DW, Koopmans R, Willoughby E, Li DKB. Serial MRI studies in multiple sclerosis: a new method for assessing disease activity in both chronic progressive and relapsing patients. Abstract. Neurology 1988;38(Suppl 1):255.
46. Kiel MK, Greenspun B, Grossman RI. Magnetic resonance imaging and degree of disability in multiple sclerosis. Arch Phys Med Rehabil 1988;69:11–13.
47. Rao SM, Leo GJ, Haughton VM, St. Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39:161–166.
48. Uhlenbrock D, Seidel D, Gehlen W, et al. MR imaging in multiple sclerosis: comparisons with clinical, CSF, and visual evoked potential findings. AJNR 1988;9:59–67.
49. Medaer R, Nelissen E, Appel B, Swerto M, Geutjene J, Collaert H. Magnetic resonance imaging and cognitive functioning in multiple sclerosis. J Neurol 1987;235:86–89.
50. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Nuwer MR. Clinical experience with azathioprine: the pros. Neurology 1988;38(Suppl 2):20–23.